References
- Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet 2021; 398: 1002–14. doi: 10.1016/S0140-6736(21)01206-X
- Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U; ESMO Guidelines Committee. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 30: 1884–901. doi: 10.1093/annonc/mdz411
- Hribernik N, Boc M, Ocvirk J, Knez-Arbeiter J, Mesti T, Ignjatovic M, et al. Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab - real-world experience. Radiol Oncol 2020; 54: 119–27. doi: 10.2478/raon-2020-0003
- Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol 2022; 40: 127–37. doi: 10.1200/JCO.21.02229
- Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 2020; 6: 38. doi: 10.1038/s41572-020-0160-6
- Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018; 378: 158–68. doi: 10.1056/NEJMra1703481
- Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, et al; ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33: 1217–38. doi: 10.1016/j.annonc.2022.10.001
- Balaji A, Zhang J, Wills B, Marrone KA, Elmariah H, Yarchoan M, et al. Immune-related adverse events requiring hospitalization: Spectrum of toxicity, treatment, and outcomes. J Oncol Pract 2019; 15: e825–e834. doi: 10.1200/JOP.18.00703
- Lopci E, Hicks RJ, Dimitrakopoulou-Strauss A, Dercle L, Iravani A, Seban RD, et al. Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F] FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. Eur J Nucl Med Mol Imaging 2022; 49: 2323–41. doi: 10.1007/s00259-022-05780-2
- Iravani A, Hicks RJ. Imaging the cancer immune environment and Its response to pharmacologic intervention, Part 1: the role of 18F-FDG PET/CT. J Nucl Med 2020; 61: 943–50. doi: 10.2967/jnumed.119.234278
- Hribernik N, Huff DT, Studen A, Zevnik K, Klaneček Ž, Emamekhoo H, et al. Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study. Eur J Nucl Med Mol Imaging 2022; 49: 1857–69. doi: 10.1007/s00259-021-05650-3
- Aide N, Iravani A, Prigent K, Kottler D, Alipour R, Hicks RJ. PET/CT variants and pitfalls in malignant melanoma. Cancer Imaging 2022; 22: 3. doi: 10.1186/s40644-021-00440-4
- Wong A, Callahan J, Keyaerts M, Neyns B, Mangana J, Aberle S, et al. 18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma. Cancer Imaging 2020; 20: 36. doi: 10.1186/s40644-020-00313-2
- Huff DT, Ferjancic P, Namías M, Emamekhoo H, Perlman SB, Jeraj R. Image intensity histograms as imaging biomarkers: application to immune-related colitis. Biomed Phys Eng Express 2021; 7: 10.1088/2057-1976/ac27c3. doi: 10.1088/2057-1976/ac27c3
- Cho SY, Lipson EJ, Im HJ, Rowe SP, Gonzalez EM, Blackford A, et al. Prediction of rresponse to immune checkpoint inhibitor therapy using early-time-point 18F-FDG PET/CT imaging in patients with advanced melanoma. J Nucl Med 2017; 58: 1421–8. doi: 10.2967/jnumed.116.188839
- Sachpekidis C, Kopp-Schneider A, Pan L, Papamichail D, Haberkorn U, Hassel JC, et al. Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma. Eur J Nucl Med Mol Imaging 2021; 48: 1932–43. doi: 10.1007/s00259-020-05137-7
- Anderson TM, Chang BH, Huang AC, Xu X, Yoon D, Shang CG, et al. FDG PET/CT imaging 1 week after a single dose of pembrolizumab predicts treatment response in patients with advanced melanoma. Clin Cancer Res 2024; 24: OF1–OF10. doi: 10.1158/1078-0432.CCR-23-2390
- Taghanaki SA, Zheng Y, Kevin Zhou S, Georgescu B, Sharma P, Xu D, Comaniciu D, et al. Combo loss: Handling input and output imbalance in multi-organ segmentation. Comput Med Imaging Graph 2019; 75: 24–33. doi: 10.1016/j.compmedimag.2019.04.005
- Wang H, Zhang N, Huo L, Zhang B. Dual-modality multi-atlas segmentation of torso organs from [18F]FDG-PET/CT images. Int J Comput Assist Radiol Surg 2019; 14: 473–82. doi: 10.1007/s11548-018-1879-3
- Adashek JJ, Subbiah IM, Matos I, Garralda E, Menta AK, Ganeshan DM, et al. Hyperprogression and immunotherapy: Fact, fiction, or alternative fact? Trends Cancer 2020; 6: 181–91. doi: 10.1016/j.trecan.2020.01.005
- National Cancer Institute (NCI). NCI Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0.2021. [internet]. [cited 2023 Oct 23]. Available at:
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5x11.pdf - Nelson EK, Piehler B, Eckels J, Rauch A, Bellew M, Hussey P, et al. LabKey Server: an open source platform for scientific data integration, analysis and collaboration. BMC Bioinformatics 2011; 12: 71. doi: 10.1186/1471-2105-12-71
- Isensee F, Jaeger PF, Kohl SAA, Petersen J, Maier-Hein KH. nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation. Nat Methods 2021; 18: 203–11. doi: 10.1038/s41592-020-01008-z
- Baiocco S, Matteucci F, Mezzenga E, Caroli P, Di Iorio V, Cittanti C, et al. SUV95th as a reliable alternative to SUVmax for determining renal uptake in [68Ga] PSMA PET/CT. Mol Imaging Biol 2020; 22: 1070–7. doi: 10.1007/s11307-019-01451-1
- Olsson-Brown A, Lord R, Sacco J, Wagg J, Coles M, Pirmohamed M. Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction. Endocr Connect 2020; 9: 318–25. doi: 10.1530/EC-19-0473
- Nadaraja S, Helsing J, Naghavi-Bezhad M, Land LH, Ruhlmann CH, Gerke O, et al. Value of 2-[18F] FDG-PET/CT in identifying immune-related adverse events in patients with melanoma or non-small cell lung cancer: a systematic scoping review. Clin Transl Imaging 2024; 12: 187–95. doi: 10.1007/s40336-024-00618-3
- Gideonse BM, Birkeland M, Vilstrup MH, Grupe P, Naghavi-Behzad M, Ruhlmann CH, et al. Organ-specific accuracy of [18F] FDG-PET/CT in identifying immune-related adverse events in patients with high-risk melanoma treated with adjuvant immune checkpoint inhibitor. Jpn J Radiol 2024; 42: 753–64. doi: 10.1007/s11604-024-01554-y
- Lopci E, Hicks RJ, Dimitrakopoulou-Strauss A, Dercle L, Iravani A, Seban RD, et al. Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. Eur J Nucl Med Mol Imaging 2022; 49: 2323–41. doi: 10.1007/s00259-022-05780-2
- Chieng JHL, Htet ZW, Zhao JJ, Tai ES, Tay SH, Huang Y, et al. Clinical presentation of immune-related endocrine adverse events during immune checkpoint inhibitor treatment. Cancers 2022; 29: 2687. doi: 10.3390/cancers14112687
- Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 2019; 16: 563–80. doi: 10.1038/s41571-019-0218-0
- Pan EY, Merl MY, Lin K. The impact of corticosteroid use during anti-PD1 treatment. J Oncol Pharm Pract 2020; 26: 814–22. doi: 10.1177/1078155219872786
- Hamidizadeh R, Eftekhari A, Wiley EA, Wilson D, Alden T, Bénard F. Metformin discontinuation prior to FDG PET/CT: A randomized controlled study to compare 24- and 48-hour bowel activity. Radiology 2018; 289: 418–25. doi: 10.1148/radiol.2018180078
- Moasses-Ghafari B, Fallahi B, Esfehani AF, Eftekhari M, Rahmani K, Eftekhari A, et al. Effect of diet on physiologic bowel 18F-FDG uptake. J Nucl Med Technol 2021; 49: 241–5. doi: 10.2967/jnmt.120.257857
- Kang JY, Kim HN, Chang Y, Yun Y, Ryu S, Shin H, et al. Gut microbiota and physiologic bowel 18F-FDG uptake. EJNMMI Res 2017; 7: 72. doi: 10.1186/s13550-017-0318-8
- Strašek K, Huff DT, Hribernik H, Santoro Fernandey VMA, Vincent T., Klaneček Ž, et al. Assessing the impact of CNN architectures for whole organ segmentation on predictive models of organ toxicity. [abstract]. APS March Meeting 2024. March 4–8, 2024; Minneapolis & Virtual. Bulletin of the American Physical Society 2024. Abstract Z18.00003